Pfizer Inc.

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-05-18 pm EDT			After hours 05:35:46 pm
25.33 ^USD	0.00%		25.32	-0.06%

06:06am	US states reject anti-vaccine bills as public health groups fight MAHA	RE
05:57am	Daiwa Securities Adjusts Price Target on Pfizer to $28 From $27, Maintains Neutral Rating	MT

Pfizer Shares Slip After Company Scraps Weight-Loss Pill

Published on 04/14/2025 at 05:09 am EDT - Modified on 04/14/2025 at 07:10 am EDT

Dow Jones

PFIZER INC.

0.00%

By Colin Kellaher

Pfizer shares moved lower in premarket trading Monday after the drugmaker said it is scrapping its experimental weight-loss pill danuglipron, keeping the company on the sidelines of the booming obesity market.

Shares of the New York company, which closed Friday at $21.91, were recently down 1.9% at $21.50 in premarket trading.

Pfizer said the move follows a review of the program's clinical data, including the case of a single participant in a dose-optimization study who experienced a potential drug-induced liver injury that resolved after discontinuing danuglipron.

Pfizer previously ended a study of a twice-daily version of danuglipron after disappointing trial results in which there were too many side effects.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

04-14-25 0709ET

Latest news about Pfizer Inc.

06:06am	US states reject anti-vaccine bills as public health groups fight MAHA	RE
05:57am	Daiwa Securities Adjusts Price Target on Pfizer to $28 From $27, Maintains Neutral Rating	MT
May. 15	Mubadala Investment dissolves share stake in Pfizer, Ford Motor, Walt Disney	RE
May. 15	Incorrect alert on Mubadala's stake in Citigroup withdrawn	RE
May. 13	Wall Street Just Got Its Wholesale Receipt
May. 13	Pfizer Inc Approves Hympavzi for Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors	CI
May. 13	European Commission approves Pfizer's Hympavzi for the treatment of adults and adolescents with hemophilia A or B with inhibitors	RE
May. 13	Pfizer Says European Commission Approves Expanded Indication for Hympavzi	MT
May. 13	Pfizer Gets Expanded European OK for Hympavzi Hemophilia Drug	DJ
May. 13	Data Feed - Fact Check: Le vaccin contre la COVID-19 de Pfizer n'est pas connu pour déclencher une infection à hantavirus	RE
May. 12	Rigel Pharmaceuticals, Inc., Arvinas, Inc. And Pfizer Inc. Enter Exclusive Global Licensing Agreement For VEPPANU	CI
May. 12	Arvinas, Pfizer Partner With Rigel Pharmaceuticals on Global VEPPANU Commercialization	MT
May. 12	Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug	RE
May. 12	Arvinas, Pfizer Tap Rigel Pharmaceuticals to Bring Veppanu to Market	DJ
May. 12	Arvinas and Pfizer enter into a transaction with Rigel Pharmaceuticals for the exclusive global rights of Veppanu	RE

Chart Pfizer Inc.

Duration

Period

PFE: Dynamic Chart

Company Profile

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (47.4%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (26.2%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (24.5%); - other (1.9%). The United States accounts for 60.8% of net sales.

Employees

75,000

Sector

Pharmaceuticals

More about the company